What makes ependymoma in infants different?
Looking at molecular makeup and MRIs to characterise infant ependymoma.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Looking at molecular makeup and MRIs to characterise infant ependymoma.
Helping children in sub-Saharan Africa with endemic Burkitt Lymphoma get diagnosed earlier.
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.
Assessing whether blocking a protein's activity could improve survival and reduce side effects.
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.
Stopping protein activity to stop anaplastic large cell lymphomas from growing.
Creating antibodies in the lab to treat diffuse midline gliomas and testing their effectiveness.
Finding why immunotherapy doesn't work for some children with sarcoma tumours.